CanSinoBio’s intranasal spray COVID-19 vaccine candidate relays positive results

CHINA – CanSinoBIO, a Chinese vaccine company, COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study. Results from a Phase I clinical trial, published in The Lancet, found that two-doses of the inhaled Ad5-nCoV vaccine can trigger a similar immune response to a single-dose of the injected version. This study also found that the inhaled version of the vaccine did not cause serious side effects, demonstrating an encouraging safety profile in the early-stage trial. The inhaled two-dose candidate…

Read More